Cytokeratin 8-MHC class I interactions: A potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line

Biochemical and Biophysical Research Communications

Volumn 441, Issue 3, 2013, Pages 618-623

  Wu, Ming Syue ^a   Li, Chia Hsuan ^a   Ruppert, Jan Gustav ^b   Chang, Chien Chung ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytokeratin; Human leukocyte antigen; Tumor immune escape

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; MONOCLONAL ANTIBODY;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONFOCAL MICROSCOPY; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; LYMPH NODE METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

CYTOKERATIN; HUMAN LEUKOCYTE ANTIGEN; TUMOR IMMUNE ESCAPE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CARCINOMA; CELL LINE, TUMOR; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPRECIPITATION; KERATIN-18; KERATIN-19; KERATIN-8; LYMPH NODES; LYMPHATIC METASTASIS; MOLECULAR SEQUENCE DATA; PROTEIN MULTIMERIZATION; TRYPSIN; TUMOR ESCAPE;

EID: 84888305567     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.105     Document Type: Article

References (31)

1. Restifo N.P., Wunderlich J.R. Principles of tumor immunity: biology of cellular immune responses. Biologic Therapy of Cancer 1996, 3-21. JB Lippincott Co., Philadelphia, PA. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
2. Fox B.A., Schendel D.J., Butterfield L.H., et al. Defining the critical hurdles in cancer immunotherapy. J. Transl. Med. 2011, 9:214.
3. Chang C.-C., Campoli M., Ferrone S. Classical and non-classical HLA class I antigen and NK cell activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 2005, 93:189-234.
4. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008, 27:5869-5885.
5. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother. 2008, 57:1719-1726.
6. Chen H.C., Chou A.S., Liu Y.C., et al. Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ. Lab. Invest. 2011, 91:1502-1513.
7. Barnstable C.J., Bodmer W.F., Brown G., et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978, 14:9-20.
8. Russo C., Ng A.K., Pellegrino M.A., et al. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics 1983, 118:23-35.
9. Sernee M.F., Ploegh H.L., Schust D.J. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol. Immunol. 1998, 35:177-188.
10. Perosa F., Luccarelli G., Prete M., et al. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J. Immunol. 2003, 171:1918-1926.
11. Desai S.A., Wang X., Noronha E.J., et al. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta2-microglobulin-free HLA class I heavy chains. J. Immunol. 2000, 165:3275-3283.
12. Lampson L.A., Fisher C.A., Whelan J.P. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J. Immunol. 1983, 30:2471-2478.
13. Bandoh N., Ogino T., Cho H.S., et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005, 66:185-194.
14. Wang X., Campoli M., Cho H.S., et al. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J. Immunol. Methods 2005, 299:139-151.
15. Ogino T., Wang X., Kato S., et al. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003, 62:382-393.
16. Chang C.-C., Ogino T., Mullin D.W., et al. Defective HLA class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J. Biol. Chem. 2006, 281:18763-18773.
17. Shevchenko A., Tomas H., Havlis J., et al. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 2006, 1:2856-2860.
18. Atwood J.W., Norkin L.C. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J. Virol. 1989, 63:4474-4477.
19. Coulombe P.A., Wong P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat. Cell Biol. 2004, 6:699-706.
20. Moll R., Franke W.W., Schiller D.L., et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31:11-24.
21. Barak V., Goike H., Panaretakis K.W., et al. Clinical utility of cytokeratins as tumor markers. J. Clin. Biochem. 2004, 37:529-540.
22. Hendrix M.J., Seftor E.A., Chu Y.W., et al. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 1996, 15:507-525.
23. Godfroid E., Geuskens M., Dupressoir T., et al. Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J. Cell Sci. 1991, 99:595-607.
24. Gires O., Andratschke M., Schmitt B., et al. Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells. Biochem. Biophys. Res. Commun. 2005, 328:1154-1162.
25. Matthias C., Mack B., Berghaus A., et al. Keratin 8 expression in head and neck epithelia. BMC Cancer 2008, 8:267.
26. Wells M.J., Hatton M.W.C., Hewlett B., et al. Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes. J. Biol. Chem. 1997, 272:28574-28581.
27. Hembrough T.A., Li L., Gonias S.L. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J. Biol. Chem. 1996, 271:25684-25691.
28. Liu F., Chen Z., Wang J., et al. Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 2008, 10:1275-1284.
29. Andrei C., Dazzi C., Lotti L., et al. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell 1999, 10:1463-1475.
30. Ladasky J.J., Shum B.P., Canavez F., et al. Residue 3 of β2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody. Immunogenetics 1999, 49:312-320.
31. Trymbulak W.P., Zeff R.A. Mutants of human beta2-microglobulin map an immunodominant epitope within the three-stranded beta-pleated sheet. Transplantation 1997, 64:640-645.